• Q3 receipts from customers increased 14% to $0.73m
• Cash on hand $1.34m, decreased 38% from prior quarter
• Operating cash outflow $0.75m, increased from $0.42m in prior corresponding period

Uscom Limited (ASX: UCM) has released its Appendix 4C cash flow report for the quarter ending 31st March 2025. The key highlights include:- Revenue: Q3 receipts from customers increased 14% to $0.73m from $0.64m in the prior quarter, but decreased 3% from $0.75m in the prior corresponding period.- Cash Flow: Uscom reported cash on hand of $1.34m, a decrease of 38% from the prior quarter of $2.17m. Operating cash outflow was $0.75m, an increase from an outflow of $0.42m in the prior corresponding period.- Expenditure: Expenditure for the quarter increased, with staff costs of $0.68m up 28% from $0.53m in the prior corresponding period, and advertising and marketing expenses up 10% to $0.33m.Executive Chairman Professor Rob Phillips commented that Q3 was an 'extraordinary period' due to the global trade war, but Uscom still achieved a 14% increase in sales revenue over the prior quarter. The company has continued to reach operational milestones, including clinical achievements, new partnerships, and regulatory approvals in China.

Uscom is globally well poised for growth with new products, new partnerships and expansionary operational strategies in preparation for the stabilization of global geopolitics and the re-emergence of a rational commercial environment and the restoration of Uscom's high trend growth trajectory.